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1. INTRODUCTION {#mgg3877-sec-0005}
===============

Hepatic glycogen storage diseases (GSDs) are a group of inborn errors of metabolism that include 11 different diseases caused by defects in glycogenolytic pathway. These defects are caused by pathogenic variants that result in enzymatic deficiencies for glycogen breakdown or synthesis, or problems in proteins that regulate glycogen metabolism. The consequence is accumulation of glycogen in tissues, especially in liver (Chen & Zhong, [2013](#mgg3877-bib-0016){ref-type="ref"}).

The general GSD frequency is 1 in 2,000--43,000 and their distribution is pan‐ethnic (Özen, [2007](#mgg3877-bib-0048){ref-type="ref"}; Vega et al., [2016](#mgg3877-bib-0071){ref-type="ref"}). Some forms of GSDs are underestimated due to mild symptoms, rare occurrence, or difficult diagnostic methods. Symptoms may range from neonatal to almost asymptomatic, and the age of onset, severity, morbidity, mortality, and prognosis are dependent of causal variants (Kishnani et al., [2014](#mgg3877-bib-0033){ref-type="ref"}, [2010](#mgg3877-bib-0034){ref-type="ref"}; Laforêt, Weinstein, & Smit, [2012](#mgg3877-bib-0036){ref-type="ref"}; Özen, [2007](#mgg3877-bib-0048){ref-type="ref"}; Wang et al., [2012](#mgg3877-bib-0074){ref-type="ref"}). The main clinical symptoms are hypoglycemia and hepatomegaly, and long‐term complications are frequent (Burda & Hochuli, [2015](#mgg3877-bib-0009){ref-type="ref"}).

Different types of GSDs can be clinically indistinguishable and need liver biopsy, an invasive method. In this aim, the molecular diagnosis using blood samples generates an accurate diagnosis and allows prognosis and genetic counseling (Choi et al., [2017](#mgg3877-bib-0018){ref-type="ref"}; Davit‐Spraul et al., [2011](#mgg3877-bib-0022){ref-type="ref"}). Similar diseases in clinical symptoms, metabolic routes, or genetic features are a challenge to diagnose. In this aim, next‐generation sequencing (NGS) is an important tool to determine the cause of the disease with accuracy and efficacy, allowing a more suitable treatment.

Only two previous studies have characterized 13 patients with GSD Ia and Ib in Brazilian population (Carlin, Scherrer, Tommaso, Bertuzzo, & Steiner, [2013](#mgg3877-bib-0014){ref-type="ref"}; Reis et al., [2001](#mgg3877-bib-0053){ref-type="ref"}).

In the present study, we describe the results of variant analysis in a cohort of 125 patients with hepatic GSD suspected diagnosis by NGS.

2. MATERIAL AND METHODS {#mgg3877-sec-0006}
=======================

This study was approved by the Research Ethics Committee of Hospital de Clínicas de Porto Alegre (project no. 15‐0556), and all patients and guardians provided written informed consent for participation.

Were analyzed 125 patients with clinical symptoms of hepatic GSD. Blood samples were collected in EDTA vacuum container. DNA was extracted with Easy‐DNA Purification kit (Thermo Fisher). DNA samples were quantificated in NanoDrop 1000 (Thermo Fisher) and through Qubit dsDNA HS Assay Kit (Thermo Fisher).

The gene panel amplicon was designed with Ion Ampliseq Designer software (Thermo Fisher), and included the exons and flanking 40 bp into introns of 11 genes involved in hepatic GSD (Table [1](#mgg3877-tbl-0001){ref-type="table"}). The sequencing was performed in Ion Torrent PGM platform (Applied Biosystems), based in PCR amplification with minimal coverage of 200X. Base calling and sequence read quality assessments were performed using Torrent Suite 5.0.5. Alignment of the sequence reads to a reference human genome (GRCh37.p13) was performed using IonStates alignment.

###### 

Genes and diseases diagnosed in gene panel

  GSD type   Gene        OMIM     Location          Enzyme deficiency                 Inheritance   Incidence              Main clinical symptoms   Mutations in HGMD         
  ---------- ----------- -------- ----------------- --------------------------------- ------------- ---------------------- ------------------------ ------------------- ----- -----------
  0          GYS2        138571   *12p12.2*         glycogen synthase                 AR                                   Yes                      No                  No    18 (19)
  Ia         *G6PC*      232200   *17q21*           Glucose‐6‐phosphatase             AR            1 in 50,000--100,000   Yes                      Yes                 Yes   106 (111)
  Ib         *SLC37A4*   232220   *11q23.3*         Glucose‐6‐phosphate transporter   AR                                   Yes                      Yes                 Yes   101 (110)
  III        AGL         232400   *1p21*            glycogen debranching enzyme       AR            1 in 100,000           Yes                      Yes                 Yes   155 (239)
  IV         *GBE1*      232500   *3p12.3*          glycogen branching enzyme         AR            1 to 500,000           No                       Yes                 No    50 (69)
  VI         *PYGL*      232700   *14q21‐q22*       liver glycogen phosphorylase      AR            1 in 65,000--85,000    Yes                      Yes                 Yes   31 (43)
  XIa        *PHKA2*     306000   *Xp22.2‐p22.1*    phosphorylase kinase α subunit    X‐linked                             Yes                      Yes                 No    80 (104)
  XIb        *PHKB*      261750   *16q12‐q13*       phosphorylase kinase β subunit    AR                                   Yes                      Yes                 No    18 (24)
  XIc        *PHKG2*     613027   *16p12.1‐p11.2*   phosphorylase kinase γ subunit    AR                                   Yes                      Yes                 Yes   19 (31)
  XI         *SLC2A2*    612933   *3q26.1‐q26.2*    facilitated glucose transporter   AR                                   Yes                      Yes                 Yes   66 (78)
  XII        *ALDOA*     611881   *16q22‐q24*       aldolase A                        AR                                   No                       Yes                 No    7 (8)

John Wiley & Sons, Ltd

The softwares Enlis Genome Research (LLC), Variant Effect Predictor (Ensembl), Ion Reporter (Thermo Fisher) and Varstation^®^ (Varstation) were used to detect and classify variants. To determine the variants causing disease, the following were considered: ACMG guideline (Richards et al., [2015](#mgg3877-bib-0055){ref-type="ref"}); allele frequency under 1% in the 1,000 Genomes Project (Sabeti, 2015); location in exon or borderlines; impact in the protein (missense, nonsense or splicing sites); and pathogenicity by predictors SIFT and Polyphen 2. For score of pathogenicity predictions in missense novel variants were used the softwares Polyphen 2 (Adzhubei et al., [2010](#mgg3877-bib-0003){ref-type="ref"}), SIFT (Vaser, Adusumalli, Leng, Sikic, & Ng, [2016](#mgg3877-bib-0070){ref-type="ref"}), PROVEAN (Choi, Sims, Murphy, Miller, & Chan, [2012](#mgg3877-bib-0019){ref-type="ref"}), Mutation Teaster (Schwarz, Cooper, Schuelke, & Seelow, [2014](#mgg3877-bib-0061){ref-type="ref"}), Pmut 2017 (López‐Ferrando, Gazzo, Cruz, Orozco, & Gelpí, [2017](#mgg3877-bib-0042){ref-type="ref"}), SNP&Go (Profiti, Martelli, & Casadio, [2017](#mgg3877-bib-0050){ref-type="ref"}), PhDSNP (Capriotti & Fariselli, [2017](#mgg3877-bib-0013){ref-type="ref"}), Panther (Thomas et al., [2003](#mgg3877-bib-0066){ref-type="ref"}), SNAP2 (Hecht, Bromberg, & Rost, [2015](#mgg3877-bib-0028){ref-type="ref"}) and MutPred (Pejaver et al., [2017](#mgg3877-bib-0049){ref-type="ref"}). For splice site variants, Genescan (Burge & Karlin, [1997](#mgg3877-bib-0010){ref-type="ref"}) and MaxEntScan were used (Yeo & Burge, [2003](#mgg3877-bib-0076){ref-type="ref"}).

Validations of NGS results were realized by Sanger sequencing in patients and in parents when the sample was available. The unbiased capture and deep coverage of each coding exon and adjacent intronic region of all genes in this panel ensure accuracy of variant detection.

3. RESULTS {#mgg3877-sec-0007}
==========

We analyzed 125 patients with clinical suspicion of hepatic GSD. All samples were successfully sequenced. We found 63 different variants in 110 families, and 27 of those were new variants (Tables [2](#mgg3877-tbl-0002){ref-type="table"} and Appendix [S1](#mgg3877-sup-0001){ref-type="supplementary-material"}).

###### 

Variants found in 125 patients with hepatic GSDs, their references, frequencies in databanks, and ACMG classification

  Gene GenBank          Allele              Protein       Location                                                                                         Reference                                                                  ExAC Frequence            ACMG                  
  --------------------- ------------------- ------------- ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------- ------------------------- --------------------- ---------------------
  *G6PC NM_000151*      c.70C \> T          p.Gln24\*     E1                                                                                               Rocha, Cabral, and Vilarinho ([2000](#mgg3877-bib-0056){ref-type="ref"})                             PM2, PVS1             Probably pathogenic
  c.77delC              p.Ser26fs           E1            Lei et al. ([1995](#mgg3877-bib-0037){ref-type="ref"})^\#^                                       0.00006                                                                    PM2, PP5, PVS1            Pathogenic            
  c.113A \> T           p.Asp38Val          E1            ChevalierPorst et al. ([1996](#mgg3877-bib-0017){ref-type="ref"})                                0.000008                                                                   PM1, PM2, PP2, PP3, PP5   Probably pathogenic   
  c.161A \> C           p.Gln54Pro          E1            Trioche et al. ([2000](#mgg3877-bib-0067){ref-type="ref"})                                                                                                                  PM1, PM2, PP2, PP3        Probably pathogenic   
  c.189G \> C           p.Trp63Cys          E1            New                                                                                                                                                                         PM1, PM2, PP2, PP3        Probably pathogenic   
  c.202G \> A           p.Gly68Arg          E1            Reis et al. ([2001](#mgg3877-bib-0053){ref-type="ref"})                                                                                                                     PM1, PM2, PP2, PP3        Probably pathogenic   
  c.231−1G \> A                             I1            Akanuma et al. ([2000](#mgg3877-bib-0004){ref-type="ref"})                                                                                                                  PM2                       Uncertain             
  c.247C \> T           p.Arg83Cys          E2            Lei et al. ([1993](#mgg3877-bib-0039){ref-type="ref"})                                           0.0005                                                                     BS1, PM1, PP2, PP3, PP5   Uncertain             
  c.323C \> T           p.Thr108Ile         E2            Trioche et al. ([2000](#mgg3877-bib-0067){ref-type="ref"})                                                                                                                  PM1, PM2, PP2, PP3        Probably pathogenic   
  c.401_402delCT        p.Thr134 = fs       E3            New                                                                                                                                                                         PM2                       Uncertain             
  c.439A \> T           p.Arg147\*          E3            New\*                                                                                            0.000008                                                                   PM1, PM2, PVS1            Pathogenic            
  c.509G \> A           p.Arg170Gln         E4            Barkaoui et al. ([2007](#mgg3877-bib-0007){ref-type="ref"})                                      0.00001                                                                    PM1, PM2, PP2, PP3        Probably pathogenic   
  c.563‐3C \> G                             I4            Kishnani et al. ([2009](#mgg3877-bib-0035){ref-type="ref"})                                                                                                                 PM2                       Uncertain             
  c.809G \> T           p.Gly270Val         E5            Lei et al. ([1995](#mgg3877-bib-0037){ref-type="ref"})                                           0.00001                                                                    PM2, PP2, PP3             Uncertain             
  c.969C \> A           p.Tyr323\*          E5            Calderaro et al. ([2013](#mgg3877-bib-0012){ref-type="ref"})                                     0.000008                                                                   PM2, PVS1                 Probably pathogenic   
  c.1012G \> T          p.Val338Phe         E5            Rake et al. ([2000](#mgg3877-bib-0052){ref-type="ref"})                                          0.00001                                                                    PM2, PP2, PP3             Uncertain             
  c.1039C \> T          p.Gln347\*          E5            Lei, Pan, Shelly, Liu, and Chou ([1994](#mgg3877-bib-0038){ref-type="ref"})                      0.0002                                                                     BS1, PP5, PVS1            Uncertain             
  *SLC37A4 NM_001467*   c.59G \> A          p.Gly20Asp    E3                                                                                               Veiga da Cunha et al. ([1998](#mgg3877-bib-0072){ref-type="ref"})          0.00001                   PM1, PM2, PP2, PP3    Probably pathogenic
  c.92_94delTCT         p.Phe31_Ser32del    E3            New                                                                                                                                                                         PM2                       Uncertain             
  c.344_345dupGG        p.Leu116Glyfs       E4            Galli et al. ([1999](#mgg3877-bib-0024){ref-type="ref"})                                         0.00001                                                                    PM2, PVS1                 Probably pathogenic   
  c.446G \> A           p.Gly149Glu         E5            Galli et al. ([1999](#mgg3877-bib-0024){ref-type="ref"})                                         0.00002                                                                    PM1, PM2, PP2, PP3        Probably pathogenic   
  c.547T \> C           p.Cys183Arg         E5            Veiga da Cunha et al. ([1998](#mgg3877-bib-0072){ref-type="ref"})                                                                                                           PM1, PM2, PP2, PP3        Probably pathogenic   
  c.557T \> C           p.Leu186Pro         E5            New                                                                                                                                                                         PM1, PM2, PP2, PP3        Probably pathogenic   
  c.703_705delGTG       p.Val236del         E7            Hou et al. ([1999](#mgg3877-bib-0031){ref-type="ref"})                                                                                                                      PM2, PP5                  Uncertain             
  c.899G \> A           p.Arg300His         E9            Marcolongo et al. ([1998](#mgg3877-bib-0045){ref-type="ref"})                                    0.00003                                                                    PM1, PM2, PP2, PP3        Probably pathogenic   
  c.1042_1043delCT      p.Leu348fs          E9            Veiga da Cunha et al. ([1998](#mgg3877-bib-0072){ref-type="ref"})                                                                                                           BS1, PP5, PVS1            Uncertain             
  c.1179G \> A          p.Trp393\*          E10           New\*                                                                                            0.00002                                                                    PM2, PVS1                 Probably pathogenic   
  *AGL NM_000642*       c.293 + 2T\>A                     I3                                                                                               Hadjigeorgiou et al. ([1999](#mgg3877-bib-0027){ref-type="ref"})                                     PM2                   Uncertain
  c.325G \> T           p.Val109Leu         E4            New\*                                                                                            0.00009                                                                    BP1, PM1, PM2, PP3,       Uncertain             
  c.744G \> A           p.Trp248\*          E6            New                                                                                                                                                                         PM1, PM2, PVS1            Pathogenic            
  c.1383G \> A          p.Trp461\*          E11           New\*                                                                                            0.000008                                                                   PM1, PM2, PVS1            Pathogenic            
  c.1481G \> A          p.Arg494His         E12           Goldstein et al. ([2010](#mgg3877-bib-0026){ref-type="ref"})                                     0.008                                                                      BP1, BS1, PM1, PP3        Probably Benign       
  c.1571G \> A          p.Arg524His         E12           Lucchiari et al. ([2006](#mgg3877-bib-0044){ref-type="ref"})                                     0.000008                                                                   BP1, PM1, PM2, PP3        Uncertain             
  c.1734A \> T          p.Arg578Ser         E13           New                                                                                                                                                                         BP1, PM1, PM2, PP3        Uncertain             
  c.1858_1859delCT      p.Leu620Valfs       E14           New                                                                                                                                                                         PM2, PVS1                 Probably pathogenic   
  c.2455_2458delAAAC    p.Lys819 = fs       E19           New                                                                                                                                                                         PM2, PVS1                 Probably pathogenic   
  c.2728C \> T          p.Arg910\*          E21           Lucchiari et al. ([2006](#mgg3877-bib-0044){ref-type="ref"})                                     0.000008                                                                   PM1, PM2, PVS1            Pathogenic            
  c.2904_2905insT       p.Tyr969Leufs       E22           New                                                                                                                                                                         PM2, PVS1                 Probably pathogenic   
  c.3214_3215delGA      p.Glu1072Aspfs      E24           Goldstein et al. ([2010](#mgg3877-bib-0026){ref-type="ref"})                                     0.000008                                                                   PM2, PVS1                 Probably pathogenic   
  c.3475_3476insA       p.Gln1159fs         E26           New                                                                                                                                                                         PM2, PVS1                 Probably pathogenic   
  c.3484C \> T          p.Gln1162\*         E26           New                                                                                                                                                                         PM1, PM2, PVS1            Pathogenic            
  c.3625C \> T          p.Gln1209\*         E27           New                                                                                                                                                                         PM1, PM2, PVS1            Pathogenic            
  c.3814_3815delG       p.Arg1272 = fs      E28           New                                                                                                                                                                         PM2, PVS1                 Probably pathogenic   
  c.3904delA            p.Lys1302fs         E29           New                                                                                                                                                                         PM2, PVS1                 Probably pathogenic   
  c.3980G \> A          p.Trp1327\*         E30           Lucchiari et al. ([2002](#mgg3877-bib-0043){ref-type="ref"})                                     0.00002                                                                    PM1, PM2, PVS1            Pathogenic            
  c.4528_4529insA       p.Tyr1510\*         E34           Shen and Chen ([2002](#mgg3877-bib-0062){ref-type="ref"})                                        0.00001                                                                    PM2, PVS1                 Probably pathogenic   
  *PYGL NM_001163940*   c.131G \> A         p.Arg44His    E1                                                                                               Hoogeveen et al. ([2015](#mgg3877-bib-0030){ref-type="ref"})                                         PM2, PP2, PP3         Uncertain
  c.697G \> A           p.Gly233Ser         E6            New\*                                                                                            0.00004                                                                    PM2, PP2, PP3             Uncertain             
  *PHKA2 NM_000292*     c.133C \> T         p.Arg45Trp    E2                                                                                               Beauchamp et al. ([2007](#mgg3877-bib-0008){ref-type="ref"})                                         PM1, PM2, PP2, PP3    Probably pathogenic
  c.557G \> A           p.Arg186His         E6            Burwinkel et al. ([1996](#mgg3877-bib-0011){ref-type="ref"})                                                                                                                PM1, PM2, PP2, PP3, PP5   Probably pathogenic   
  c.883C \> T           p.Arg295Cys         E9            Ban, Sugiyama, Goto, Mizutani, and Togari ([2003](#mgg3877-bib-0006){ref-type="ref"})                                                                                       PM1, PM2, PP2, PP3, PP5   Probably pathogenic   
  c.1963 + 1G\>A                            I18           Rodríguez‐Jimenez et al. ([2017](#mgg3877-bib-0057){ref-type="ref"})                             0.00001                                                                    PM2                       Uncertain             
  c.2452C \> T          p.Gln818\*          E22           New                                                                                                                                                                         PM2, PVS1                 Probably pathogenic   
  c.3614C \> T          p.Pro1205Leu        E33           van den Berg et al. ([1995](#mgg3877-bib-0068){ref-type="ref"})                                                                                                             PM2, PP2, PP3, PP5        Uncertain             
  c.3629G \> A          p.Gly1210Glu        E33           Rudolfova, Slováčková, Trbušek, Pešková, and Kozák ([2001](#mgg3877-bib-0058){ref-type="ref"})                                                                              PM2, PP2, PP3             Uncertain             
  *PHKB NM_000293*      c.572_576delAGATT   p.Gln191Hfs   E6                                                                                               New\*                                                                      0.000008                  BS1, PVS1             Uncertain
  c.1972‐2A \> G                            I20           New                                                                                                                                                                         PM2                       Uncertain             
  c.2081C \> G          p.Ser694\*          E22           New                                                                                                                                                                         PM2, PVS1                 Probably pathogenic   
  c.2181delT            p.Leu728fs          E22           New                                                                                                                                                                         PM2, PVS1                 Probably pathogenic   
  *PHKG2 NM_000294*     c.454C \> T         p.Arg152\*    E6                                                                                               New\*                                                                      0.000008                  PM1, PM2, PVS1        Pathogenic
  c.502C \> T           p.Arg168\*          E6            Davit Spraul et al. ([2011](#mgg3877-bib-0022){ref-type="ref"})                                  0.00001                                                                    PM1, PM2, PVS1            Pathogenic            
  c.835C \> T           p.Arg279Cys         E9            New                                                                                                                                                                         PM1, PM2, PP2, PP3        Probably pathogenic   
  c.927 + 1G\>A                             I9            New                                                                                                                                                                         PM2                       Uncertain             

E: Exon; I: Intron; New\*: New mutation related to hepatic GSDs, however presented in data banks; \#discordance between literature nomenclature and HGVS rules.
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Seventy‐five patients are men. The patients included in the study are from all Brazilian regions: 63 from the southeast (SP *n* = 48, RJ *n* = 2, MG *n* = 10, ES *n* = 3), 50 from the south (RS *n* = 46, SC *n* = 4), eight from the northeast (BA *n* = 2, CE *n* = 3, PB *n* = 3), two from the Midwest (DF = 1, MT *n* = 1) and two from the north (PA *n* = 2) (Appendix [S1](#mgg3877-sup-0001){ref-type="supplementary-material"}).

Both pathogenic variants were identified in 118 patients confirming the molecular diagnosis of hepatic GSD. For two patients, only one variant was found (patients 84 and 85). In five patients, no variant was identified (Appendix [S1](#mgg3877-sup-0001){ref-type="supplementary-material"}). All identified variants were confirmed by Sanger sequencing and investigated in literature or databanks (Tables [2](#mgg3877-tbl-0002){ref-type="table"} and Appendix [S1](#mgg3877-sup-0001){ref-type="supplementary-material"}).

Eight families included in this study had multiple affected individuals. For patients 5, 11, and 12 (11 and 12 are sisters), their parents reported consanguinity (Appendix [S1](#mgg3877-sup-0001){ref-type="supplementary-material"}). These information were considered while counting alleles.

Sixty‐three alleles were identified, in which 26 are missense variants (41.2%), 16 are nonsense variants (25.3%), six are splice site variants (9.5%), 11 deletions (17.4%), three insertions (4.7%) and one duplication (1.5%) (Table [2](#mgg3877-tbl-0002){ref-type="table"}).

Among the 125 patients analyzed, 53 were genetically diagnosed with GSD Ia (42%), 23 with GSD Ib (18%), 14 with GSD III (11%), two with GSD VI (1.6%), 16 GSD IXa (12%), six with GSD IXb (4.8%), six with GSD IXc (4.8%), and five were not diagnosed (4%) (Appendix [S1](#mgg3877-sup-0001){ref-type="supplementary-material"}).

The most frequent variants in patients were p.Arg83Cys, observed in 39 alleles (18.5%), and p.Gln347\* present in 14 alleles (6.6%), both in *G6PC* gene, causing GSD Ia. The other frequent variant, p.Leu348Valfs in *SLC37A4* gene, was observed in 10% of alleles causing GSD Ib.

Variants not described in the literature were evaluated for protein impact by nine in silico pathogenicity prediction algorithms. All new missense variants were predicted as pathogenic. In the bioinformatics analyses of new splice site variants, all were confirmed to modify the exon--intron structures in different forms importantly, showing sufficient entropy forces to perform the incorrect splicing.

4. DISCUSSION {#mgg3877-sec-0008}
=============

This is one of the largest screening of variants causing the different forms of GSDs in patients, including 125 patients and describing 63 different variants, of which 27 are novel.

The GSD Ia and GSD Ib represent 60% of the analyzed patients. In other analyzed cohorts, Vega et al. ([2016](#mgg3877-bib-0071){ref-type="ref"}) reported more than three‐quarters of patients who had GSD III or GSD IXa (39% of each type), and Özen ([2007](#mgg3877-bib-0048){ref-type="ref"}) found GSD type IXa as the most common form of the disease. These data reflect the differences among populations, the existence of private pathogenic variants, and the differences in prevalence of variants in GSDs.

GSD type Ia is the most widely distributed. The most frequent pathogenic variant found in this work was p.Arg83Cys, present in 18.5% of all patients and 39% of alleles in GSD Ia patients. This is one of the most important variant found around the world in patients with GSD Ia (Chou & Mansfield, [2008](#mgg3877-bib-0021){ref-type="ref"}; Matern, Seydewitz, Bali, Lang, & Chen, [2002](#mgg3877-bib-0046){ref-type="ref"}). This variant in *G6PC* is in the active center of the enzyme G6Pase and presented no detectable activity in transient expression assays (Lei, Shelly, Pan, Sidbury, & Chou, [1993](#mgg3877-bib-0039){ref-type="ref"}). p.Arg83Cys is present in 50% of alleles in French and Tunisian patients (Barkaoui et al., [2007](#mgg3877-bib-0007){ref-type="ref"}; Trioche et al., [2000](#mgg3877-bib-0067){ref-type="ref"}), 80% of Sicilian and 100% of alleles in Ashkenazi Jewish patients (Ekstein et al., [2004](#mgg3877-bib-0023){ref-type="ref"}; Stroppiano et al., [1999](#mgg3877-bib-0065){ref-type="ref"}). This variant is found in genomAD in a frequency of 0.0005 (Lek et al., [2016](#mgg3877-bib-0040){ref-type="ref"}) and appears to be in a hotspot since two other variants are observed in the same position (p.Arg83His and p.Arg83=). There are another eight variants in amino acids 80, 81, and 82, six of them being pathogenic. In the same gene, the variant p.Gln347\* was in 6.9% of all alleles or in 15% of alleles in GSD Ia. They both represent approximately 54% of variants found in GSD Ia patients.

The second most frequently found variant among all patients was p.Leu348Valfs in *SLC37A4* gene, present in 10% of patients, and 47.7% of alleles (21/44 alleles) in GSD Ib. This variant was present in 39% of Serbians patients (Skakic et al., [2018](#mgg3877-bib-0063){ref-type="ref"}) and 31% of White patients reviewed in Chou, Jun, and Mansfield ([2010](#mgg3877-bib-0020){ref-type="ref"}).

Twenty‐seven novel variants were identified among the 125 patients, observed mainly among patients with GSD type III and type IX. *AGL*, that causes GSD III, is one of the largest genes, and has the highest number of variants reported in HGMD -- The Human Gene Mutation Database (Stenson et al., [2003](#mgg3877-bib-0064){ref-type="ref"}), which proves its heterogeneity. The increased number of variants in type IX patients can be justified by their lower characterization.

Some of the novel variants have already been detected in database projects involving the search for variants in a large number of individuals but never related to patients. We investigate the variants in "The Exome Aggregation Consortium" -- ExAC -- composed of 60,706 unrelated individuals, and the Online Archive of Brazilian Mutations -- AbraOM -- composed of 609 elderly individuals, as in other databases (Lek et al., [2016](#mgg3877-bib-0040){ref-type="ref"}; Naslavsky et al., [2017](#mgg3877-bib-0047){ref-type="ref"}; Sabeti, [2015](#mgg3877-bib-0059){ref-type="ref"}). Seven of 27 novel variants were in ExAC, all in very low frequencies (Table [2](#mgg3877-tbl-0002){ref-type="table"}).

Seven different types of GSDs were found. Only types 0, IV, XI and XII were not observed among the 125 patients. The type IX represented 22.4% of the patients (12.8% of type IXa), since GSD type IX had never been described in Brazilian patients.

In two patients, only one variant was found (patients 84 and 85) instead of two. Both patients presented variants in *AGL*. This gene has the highest number of gaps in coverage of NGS and is one of the biggest genes in panel, with 36 exons. However, the gaps were analyzed by Sanger sequencing and no variant was found. The results obtained from these patients are contradictory, since the variants found in both cases are described for GSD type III; however both patients presented inconsistent clinical findings. One of them has Down syndrome and liver histology similar to GSD III, but no biochemical results are compatible with the disease and the patient does not present any clinical symptoms. The other patient presented hypoglycemia from birth, however, currently associated with hyponatremia and metabolic acidosis. The liver biopsy was inconclusive and not suggestive of GSD. Therefore, it is possible that variants or technical artifacts are eliminating the amplification of the mutated allele or the variants are in regulatory regions, not covered by the panel, but the absence of disease is a possibility (Hedell, Dufva, Ansell, Mostad, & Hedman, [2015](#mgg3877-bib-0029){ref-type="ref"}; Inokuchi et al., [2016](#mgg3877-bib-0032){ref-type="ref"}).

In five patients with no identified variants, the clinical suspicions are mild or inconclusive, once they did not have clear clinical indications or laboratory findings supporting the diagnosis of GSD, besides hypoglycemia and/or hepatomegaly. The NGS was a diagnostic exclusion test; therefore, it was an expected result. These patients probably do not have GSD, once hepatomegaly and hypoglycemia are difficult to distinguish from other metabolic storage disorders without more clinical findings. Another possibility is the presence of variants in nontargeted deep intronic and regulatory regions (Wang et al., [2013](#mgg3877-bib-0075){ref-type="ref"}).

Relationships of synergistic heterogeneity should be considered for GSDs, since the disease‐causing deficient enzymes share metabolic pathways, however it was not observed in the present study (Vockley, Rinaldo, Bennett, Matern, & Vladutiu, [2000](#mgg3877-bib-0073){ref-type="ref"}).

The patient 120 is possibly a GSD patient because he presented clinical symptoms such as hypoglycemia and ketonuria but no other clinical signs, however only synonymous variants were found in *GYS2* (that causes GSD type 0), which does not justify the disease.

This variety of results reflects the profile of an extremely large country with an interesting and important mix of people from all over the world. The presence of immigrants from the most diverse origins, such as Africans, Asians, and Amerindians justifies the variability of alleles found in a highly mixed population. Genetic analyses indicate that Latin Americans trace their ancestry mainly in the intermixing of Native Americans, Europeans, and Sub‐Saharan Africans. Historically, Latin America has a continuous, differential, and diverse intra‐ and intercontinental migration events, and presents higher prevalence of metabolic diseases (Adhikari, Chacón‐Duque, Mendoza‐Revilla, Fuentes‐Guajardo, & Ruiz‐Linares, [2017](#mgg3877-bib-0002){ref-type="ref"}; Chacón‐Duque et al., [2018](#mgg3877-bib-0015){ref-type="ref"}; Giolo et al., [2012](#mgg3877-bib-0025){ref-type="ref"}; Quinto‐Sánches et al., [2017](#mgg3877-bib-0051){ref-type="ref"}; Resque et al., [2016](#mgg3877-bib-0054){ref-type="ref"}).

Among the advantages of NGS diagnosis, patients undiagnosed by traditional means were investigated and correctly diagnosed in the present study. This method is especially promising for mixed populations with high level of heterogeneity. This method also allows the identification of unexpected diagnoses in the supposed typical phenotypes. Rare genetic diseases can be a diagnostic challenge, sometimes an odyssey. The NGS technologies can provide a fast diagnosis, advantages for treatment management, in reproductive choices, genetic counseling, and fertility services (Schofield et al., [2017](#mgg3877-bib-0060){ref-type="ref"}). The GSD traditional diagnosis methods involve liver biopsy, an invasive and risked method, that can be avoided with a well‐established molecular method (Bali, Chen, Austin, & Goldstein, [2016](#mgg3877-bib-0005){ref-type="ref"}; Lévesque et al., [2016](#mgg3877-bib-0041){ref-type="ref"}).

This diagnosis is an important advancement for patients with nontypical forms of disease, especially for those who need agile actions, since it evaluates 11 genes at the same time.

This was an important step to increase the knowledge about the genetics of the different types of hepatic GSDs in Brazilian patients, since they have a genetically heterogeneous origin, and it is reflected in the variability of types and variants (Vega et al., [2016](#mgg3877-bib-0071){ref-type="ref"}; Wang et al., [2013](#mgg3877-bib-0075){ref-type="ref"}). The evaluation by NGS also allows to detect cases of synergic heterogeneity that cannot be perceived by Sanger sequencing.

Differentiated therapeutic management among GSD justifies the population characterization of patients. If NGS analyses are not available or expensive, the molecular diagnosis should be conducted first through the search for the pathogenic variants p.Arg83Cys and p.Gln347\* in *G6PC* in case of GSD Ia or p.Leu348Valfs in *SLC37A4* for GSD Ib. Sanger sequencing approach is the most cost‐effective to solve up to 40% of the cases. However, for the cases without prevalent mutations or without suspected type of GSD, NGS is the most effective solution.

This study emphasizes that molecular genetic analysis is a reliable and convenient alternative to the assay of enzymatic activity in a fresh liver biopsy specimen for the diagnosis of GSDs. This type of study is an important tool for the estimation of disease progression, since different types of GSDs present variations in their clinical course and treatment, besides serving as a basis for genetic counseling and prenatal diagnosis.

The discovery of a significant number of new mutations reinforces the allelic variability of different GSDs and proves that the diagnosis of GSDs in Brazil can be challenging, showing the validity of NGS gene panel use for diagnosis.
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